Moderna lifts 2026 revenue growth outlook
CNBC · RSS · · AI-summarised by FinFlash
Moderna raised its 2026 revenue outlook, now guiding to growth of 15% to 25%, up from a prior range of up to 10%. The biotech company's CEO said newer vaccines are gaining traction, supporting the upgraded forecast. The higher guidance signals improving commercial momentum beyond the company's original expectations.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.